[HTML][HTML] CRISPR/Cas9 therapeutics: progress and prospects
T Li, Y Yang, H Qi, W Cui, L Zhang, X Fu, X He… - … and Targeted Therapy, 2023 - nature.com
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated
protein 9 (Cas9) gene-editing technology is the ideal tool of the future for treating diseases …
protein 9 (Cas9) gene-editing technology is the ideal tool of the future for treating diseases …
Targeting biomolecular condensation and protein aggregation against cancer
Biomolecular condensates, membrane-less entities arising from liquid–liquid phase
separation, hold dichotomous roles in health and disease. Alongside their physiological …
separation, hold dichotomous roles in health and disease. Alongside their physiological …
Long non-coding RNA (lncRNA) H19 in human cancer: From proliferation and metastasis to therapy
M Hashemi, MS Moosavi, HM Abed, M Dehghani… - Pharmacological …, 2022 - Elsevier
Initiation and development of cancer depend on multiple factors that mutations in genes and
epigenetic level can be considered as important drivers. Epigenetic factors include a large …
epigenetic level can be considered as important drivers. Epigenetic factors include a large …
A study of miRNAs as cornerstone in lung cancer pathogenesis and therapeutic resistance: A focus on signaling pathways interplay
Lung cancer (LC) is the most common cancer-related death globally, and many efforts have
been made to improve the patient care of LC patients, as well as the development of efficient …
been made to improve the patient care of LC patients, as well as the development of efficient …
[HTML][HTML] Cell membrane-coated nanomaterials for cancer therapy
S Zeng, Q Tang, M Xiao, X Tong, T Yang, D Yin, L Lei… - Materials Today Bio, 2023 - Elsevier
With the development of nanotechnology, nanoparticles have emerged as a delivery carrier
for tumor drug therapy, which can improve the therapeutic effect by increasing the stability …
for tumor drug therapy, which can improve the therapeutic effect by increasing the stability …
[HTML][HTML] Drugs targeting p53 mutations with FDA approval and in clinical trials
S Nishikawa, T Iwakuma - Cancers, 2023 - mdpi.com
Simple Summary Mutations in the tumor suppressor p53 (p53) occur in~ 50% of human
cancers, the majority of which are missense mutations. Mutations in p53 not only impair the …
cancers, the majority of which are missense mutations. Mutations in p53 not only impair the …
Small cell lung cancer transformation: From pathogenesis to treatment
X Yin, Y Li, H Wang, T Jia, E Wang, Y Luo, Y Wei… - seminars in Cancer …, 2022 - Elsevier
Small cell lung cancer (SCLC) is a type of neuroendocrine tumor with high malignancy and
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …
[HTML][HTML] Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies
Simple Summary Reprogramming of glucose metabolism is a hallmark of cancer and can be
targeted by therapeutic agents. Some metabolism regulators, such as ivosidenib and …
targeted by therapeutic agents. Some metabolism regulators, such as ivosidenib and …
The potential role of miRNAs in the pathogenesis of testicular germ cell tumors-A Focus on signaling pathways interplay
Testicular germ cell tumors (TGCTs) are the most common testicular neoplasms in
adolescents and young males. Understanding the genetic basis of TGCTs represents a …
adolescents and young males. Understanding the genetic basis of TGCTs represents a …
[HTML][HTML] PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Abstract Mouse double minute 2 (MDM2) is an E3 ubiquitin ligase which effectively
degrades tumor suppressor p53. In the past two decades, many MDM2 inhibitors that disrupt …
degrades tumor suppressor p53. In the past two decades, many MDM2 inhibitors that disrupt …